1,100 results on '"Yang, J.C."'
Search Results
152. 29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors
153. 30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
154. Finite element simulation and model optimization of blankholder gap and shell element type in the stamping of a washing-trough
155. New test of modulated electron capture decay of hydrogen-like 142Pm ions: Precision measurement of purely exponential decay
156. 396P Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
157. Cost-Effectiveness Of Staging PET/CT in Limited-Stage Follicular Lymphoma
158. 395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
159. 383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
160. 399P Real-world insights into patients (pts) with advanced NSCLC and MET alterations
161. 400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
162. Post-Mastectomy Radiation Therapy after Prepectoral Breast Reconstruction Is Associated with A Low Early Explantation Rate
163. Hosta species native to Korea
164. Longevity of Allium taquetii flowers depending on the holding solution
165. 1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L
166. 1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial
167. 1370P PD-L1 expression as a predictive biomarker for chemotherapy response in metastatic non-small cell lung cancer (mNSCLC)
168. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
169. 1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
170. 1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
171. 1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations
172. Angiogenesis is not Mediated by Prostate Cancer Neuropeptides
173. A Catalyst to Change Everything: MEMS/NEMS – a Paradigm of Taiwan's Nanotechnology Program
174. Investigation on the suitability of two-dimensional depth-averaged models for bend-flow simulation
175. Mechanism of improvement on fatigue life of metal by laser-excited shock waves
176. The effects of surface roughness on nanotribology of confined two-dimensional films
177. Friction and fracture properties of polysilicon coated with self-assembled monolayers
178. An assessment of genetic diversity and documentation of hybridization of Casuarina grown in Taiwan using RAPD markers
179. PP4 VALUE FRAMEWORKS IN REAL LIFE: COMMUNITY VALUES FOR MENTAL-HEALTH PROGRAMS
180. PMU113 NOVEL PEANUT-ALLERGY DESENSITIZATION TREATMENTS: WHO IS LIKELY TO CHOOSE TREATMENT AND WHY
181. Clinical Outcome and Benefit of Immune Checkpoint Inhibitors in Patients with Advanced Pulmonary Sarcomatoid Carcinoma
182. B09 The CANOPY Program: Three Phase 3 Studies Evaluating Canakinumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
183. Étude de phase II « basket » évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées présentant un réarrangement NRG1
184. P.232 There is a correlation between plasma erythropoietin levels and attention deficit hyperactivity disorder symptoms
185. P.231 The relationship between auditory evoked potentials and symptoms of attention-deficit/hyperactivity disorder in adult patients with major depressive disorder
186. OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study
187. PCN532 WOMEN'S PREFERENCES ON BENEFITS, RISKS, AND SIDE EFFECTS OF MAINTENANCE PARP INHIBITOR THERAPY IN OVARIAN CANCER
188. INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
189. PD01.04 CANOPY-A: a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC
190. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
191. Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
192. Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
193. PD2.05 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
194. CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
195. CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
196. Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
197. TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
198. OA11.01 Complex EGFR Mutations in Lung Adenocarcinoma
199. MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up
200. Particle identification and revolution time corrections for the isochronous mass spectrometry in storage rings
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.